IMGO Stock Overview
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow.
Imago BioSciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$35.86|
|52 Week High||US$35.89|
|52 Week Low||US$11.56|
|1 Month Change||121.22%|
|3 Month Change||117.99%|
|1 Year Change||101.46%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||120.13%|
Recent News & Updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth PlansNov 08
Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn SituationJul 26
Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In GrowthApr 12
We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn RateDec 08
|IMGO||US Biotechs||US Market|
Return vs Industry: IMGO exceeded the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: IMGO exceeded the US Market which returned -17.6% over the past year.
|IMGO Average Weekly Movement||30.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: IMGO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.
Volatility Over Time: IMGO's weekly volatility has increased from 18% to 31% over the past year.
About the Company
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Imago BioSciences, Inc. Fundamentals Summary
|IMGO fundamental statistics|
Is IMGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMGO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.82|
|Net Profit Margin||0.00%|
How did IMGO perform over the long term?See historical performance and comparison